Market Cap 260.90M
Revenue (ttm) 0.00
Net Income (ttm) -293.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 351,800
Avg Vol 284,742
Day's Range N/A - N/A
Shares Out 46.59M
Stochastic %K 1%
Beta -0.08
Analysts Sell
Price Target $9.50

Company Profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 617 600 7373
Address:
1500 District Avenue, Burlington, United States
ya33
ya33 May. 4 at 7:50 PM
0 · Reply
FlicFlac
FlicFlac Apr. 25 at 3:04 PM
$NERV what about dilution?
0 · Reply
Gymlover
Gymlover Apr. 15 at 4:04 PM
$NERV 💪💪✈️✈️ news dropped price target 14
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:36 PM
$NERV is going through a leadership transition, with Geoffrey Race out as president and Jim O'Connor stepping in as chief business officer.
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:27 PM
$NERV press release frames the same change more simply: Geoff Race is leaving and Jim O'Connor is being elevated into the chief business officer seat.
0 · Reply
Social_Idiot
Social_Idiot Mar. 19 at 2:43 PM
$NERV My Artifial Idiot sometimes makes good calls. The NERV of this to be green in an ocean of red.
0 · Reply
ya33
ya33 Mar. 18 at 3:53 PM
0 · Reply
BrianRix
BrianRix Mar. 16 at 3:58 PM
$NERV What is going on? I like it but i want to understand why!
0 · Reply
FilingTracker
FilingTracker Mar. 11 at 1:29 PM
$NERV Offering - up to $200 million: https://www.sec.gov/Archives/edgar/data/1598646/000119312526101196/d71904ds3.htm
0 · Reply
AnalyticalOne
AnalyticalOne Mar. 11 at 12:27 PM
$NERV exceeded earnings and revenue so what exactly is the bear case here?
0 · Reply
Latest News on NERV
Minerva initiated with an Outperform at Citizens

2026-04-15T08:40:30.000Z - 4 weeks ago

Minerva initiated with an Outperform at Citizens


Minerva appoints Jim O’Connor as chief business officer

2026-04-02T20:10:42.000Z - 5 weeks ago

Minerva appoints Jim O’Connor as chief business officer


Minerva Announces Leadership Transition

Apr 2, 2026, 4:05 PM EDT - 5 weeks ago

Minerva Announces Leadership Transition


Minerva screens first patient in roluperidone trial

2026-03-31T20:21:16.000Z - 6 weeks ago

Minerva screens first patient in roluperidone trial


Minerva Neurosciences Transcript: Stifel 2026 Virtual CNS Forum

Mar 18, 2026, 8:30 AM EDT - 2 months ago

Minerva Neurosciences Transcript: Stifel 2026 Virtual CNS Forum


Minerva price target raised to $7 from $4 at H.C. Wainwright

2026-03-12T10:10:35.000Z - 2 months ago

Minerva price target raised to $7 from $4 at H.C. Wainwright


Minerva files $200M mixed securities shelf

2026-03-11T13:25:12.000Z - 2 months ago

Minerva files $200M mixed securities shelf


Minerva Neurosciences Transcript: KOL event

Feb 3, 2026, 10:30 AM EST - 3 months ago

Minerva Neurosciences Transcript: KOL event


Minerva files to sell 94.6M shares of common stock for holders

2025-12-23T21:10:29.000Z - 5 months ago

Minerva files to sell 94.6M shares of common stock for holders


Minerva price target raised to $5 from $3 at Jefferies

2025-12-01T20:15:16.000Z - 5 months ago

Minerva price target raised to $5 from $3 at Jefferies


Minerva appoints Kaul to board of directors

2025-11-19T13:40:49.000Z - 6 months ago

Minerva appoints Kaul to board of directors


Minerva price target lowered to $4 from $5 at H.C. Wainwright

2025-11-06T11:11:07.000Z - 6 months ago

Minerva price target lowered to $4 from $5 at H.C. Wainwright


Minerva Neurosciences Earnings Call Transcript: Q1 2023

May 15, 2023, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Earnings Call Transcript: Q1 2023


Minerva Neurosciences Earnings Call Transcript: Q4 2022

Mar 8, 2023, 8:30 AM EST - 3 years ago

Minerva Neurosciences Earnings Call Transcript: Q4 2022


Minerva Neurosciences Earnings Call Transcript: Q3 2022

Nov 9, 2022, 8:00 AM EST - 3 years ago

Minerva Neurosciences Earnings Call Transcript: Q3 2022


Minerva Neurosciences Earnings Call Transcript: Q3 2021

Nov 7, 2021, 7:00 PM EST - 4 years ago

Minerva Neurosciences Earnings Call Transcript: Q3 2021


ya33
ya33 May. 4 at 7:50 PM
0 · Reply
FlicFlac
FlicFlac Apr. 25 at 3:04 PM
$NERV what about dilution?
0 · Reply
Gymlover
Gymlover Apr. 15 at 4:04 PM
$NERV 💪💪✈️✈️ news dropped price target 14
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:36 PM
$NERV is going through a leadership transition, with Geoffrey Race out as president and Jim O'Connor stepping in as chief business officer.
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:27 PM
$NERV press release frames the same change more simply: Geoff Race is leaving and Jim O'Connor is being elevated into the chief business officer seat.
0 · Reply
Social_Idiot
Social_Idiot Mar. 19 at 2:43 PM
$NERV My Artifial Idiot sometimes makes good calls. The NERV of this to be green in an ocean of red.
0 · Reply
ya33
ya33 Mar. 18 at 3:53 PM
0 · Reply
BrianRix
BrianRix Mar. 16 at 3:58 PM
$NERV What is going on? I like it but i want to understand why!
0 · Reply
FilingTracker
FilingTracker Mar. 11 at 1:29 PM
$NERV Offering - up to $200 million: https://www.sec.gov/Archives/edgar/data/1598646/000119312526101196/d71904ds3.htm
0 · Reply
AnalyticalOne
AnalyticalOne Mar. 11 at 12:27 PM
$NERV exceeded earnings and revenue so what exactly is the bear case here?
0 · Reply
Invest2Create
Invest2Create Mar. 11 at 5:14 AM
Having looked up the fundamental facts on $ASNS, its technicals look even better. Making a one-day, close-to-close 186.56% upswing on March 4, Atcelis Networks is currently holding a support level of 0.32, a 77% retracement from the March 4 high of 0.73, just above the Fibonacci retracement level of 78.6%. This mirrors “First Step” setups, as I call them, that: • $AGMH made September 8-18 • $BBGI made November 21 - December 9 and • $NERV made October 8-20 before each of those stocks made parabolic moves upward. It’s of course not a guarantee $ASNS will go up like these other stocks have, anymore than this post is anything more than considered analysis and opinion but not investment advice. But, taking these other stocks into account, $ASNS’ current setup is looking
0 · Reply
Invest2live
Invest2live Mar. 9 at 7:29 PM
$NERV 235% already; get in $HUMA and $AKBA after your DD.
0 · Reply
topstockalerts
topstockalerts Mar. 9 at 7:19 PM
$NERV biotech that previously moved on drug development updates and restructuring plans. These setups can reawaken when traders anticipate new clinical catalysts or funding clarity. Does speculation return?
0 · Reply
JonathanV
JonathanV Mar. 9 at 5:02 PM
$NERV why?
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Mar. 9 at 4:58 PM
$NERV now is distributing stage
0 · Reply
Mg_1970
Mg_1970 Mar. 9 at 4:34 PM
$NERV 😱😍😍😎
0 · Reply
topstockalerts
topstockalerts Mar. 9 at 3:42 PM
$NERV Following this closely as it continues to build momentum. Buyers are in control. Could be more upside ahead.
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Mar. 9 at 2:05 PM
$NERV .🤫
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 7:36 PM
$NERV Current Stock Price: $6.81
0 · Reply